29681-44-5

Usage

Uses

Used in Chemical Synthesis:
Methyl 5-bromonicotinate is used as a substrate in a microwave-assisted, palladium-catalyzed arylation of acetone as its TMS enol ether. This application is significant in the field of chemical synthesis, where it serves as a key intermediate for the production of various organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Methyl 5-bromonicotinate is utilized as a building block for the synthesis of various pharmaceutical compounds. Its unique chemical properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Research and Development:
Methyl 5-bromonicotinate is also used in research and development settings, where it is employed to study the properties and reactions of organic compounds. Its versatility as a substrate in chemical synthesis makes it an essential tool for scientists and researchers working in the field of organic chemistry.

InChI:InChI=1/C7H6BrNO2/c1-11-7(10)5-2-6(8)4-9-3-5/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 39620-02-5 5-bromonicotinoyl chloride 
• 186581-53-3 diazomethane 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 98555-51-2 5-Bromo-pyridine-2,3-dicarboxylic acid 
• 74-88-4 methyl iodide 
• 10400-19-8 3-pyridinecarbonyl chloride 
• 59-67-6 nicotinic acid 
• 592543-52-7 1-(1-benzhydryl-5-bromo-1,4-dihydro-pyridin-3-yl)-2,2,2-trichloro-ethanone 
• 1026535-63-6 1-benzhydryl-3-bromo-1,4-dihydro-pyridine 
• 592543-55-0 1-benzhydryl-5-bromo-1,4-dihydro-pyridine-3-carboxylic acid methyl ester 

Downstream Products

• 112193-41-6 5-bromonicotinic acid hydrazide 
• 93349-97-4 Methyl 5-(2-Furyl)nicotinate 
• 93349-98-5 Methyl 5-(3-Furyl)nicotinate 
• 93349-92-9 3-(3-nitrophenyl)-5-pyridinecarboxylic acid methyl ester 
• 93349-94-1 Methyl 5-(2-Methylphenyl)nicotinate 
• 93349-96-3 Methyl 5-(2-Methoxyphenyl)nicotinate 
• 93349-95-2 Methyl 5-(2-Nitrophenyl)nicotinate 
• 113893-00-8 methyl <3,3'-bipyridine>-5-carboxylate 
• 113893-01-9 methyl <3,4'-bipyridine>-5-carboxylate 
• 10177-13-6 methyl 5-phenylpyridine-3-carboxylate 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 128612-43-1 5,5'-Bis(methoxycarbonyl)-3,3'-bipyridine 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 38940-67-9 5-ethenyl-3-pyridinecarboxylic acid methyl ester 

Relevant academic research and scientific papers

Novel nicotine analogues with potential anti-mycobacterial activity

Tuberculosis (TB) is the second leading lethal infectious disease in the world after acquired immuno deficiency (AIDs). We have developed a series of twenty-five novel nicotine analogues with de-addiction property and tested them for their activity against Mycobacterium tuberculosis (MTB). In an effort to increase the specificity of action and directing nicotine analogues to target MTB, four promising compounds were further optimized via molecular docking studies against the Dihydrofolate reductase of MTB. After lead optimization, one nicotine analogue [3-(5-(3fluorophenyl)nicotinoyl)-1-methylpyrrolidin-2-one] exhibited minimum inhibitory concentration of 1 μg/mL (2.86 nM) against M. tuberculosis (H37Rv strain), a human pathogenic strain of clinically significant importance. Pharmacokinetic analysis of [3-(5-(3fluorophenyl)nicotinoyl)-1methylpyrrolidin-2-one] with lowest MIC value via oral route in Wistar rats revealed that at a dosage of 5 mg/kg body weight gave a maximum serum drug concentration (Cmax) of 2.86 μg/mL, Tmax of one hour and a half-life (T1/2) of more than 24 h and Volume of distribution (Vd) of 27.36 L. Whereas the parenteral (intra venous) route showed a Cmax of 3.37 μg/mL, Tmax of 0.05 h, T1/2 of 24 h and Vd equivalent to 23.18 L. The acute oral toxicity and repeated oral toxicity studies in female Wistar rats had an LD50 > 2000 mg/kg body weight. Our data suggests that nicotine derivatives developed in the present study has good metabolic stability with tunable pharmacokinetics (PK) with therapeutic potential to combat MTB. However, further in vivo studies for anti-tuberculosis activity and elucidation of mode of action could result in more promising novel drug for treating MTB. To the best of our knowledge this is the first report revealing the anti-mycobacterial potential of nicotine analogue at potential therapeutic concentrations.

Total Syntheses and Antimicrobial Activities of Pyridine Alkaloids from Rubiaceae

Pyridine alkaloids from Rubiaceae were prepared by palladium-catalyzed cross-coupling reactions of methyl 5-bromonicotinate (6) with various organometallic reagents.Baker's yeast reduction of the ketone 8 gave the levorotatory alcohol (S)-1.On this basis, the naturally occuring alcohol (+)-1 was assigned to be (R)-configurated.The alkaloids 1 and 4 show weak antimicrobial activities. - Keywords: Pyridine alkaloids; Palladium catalyst; Baker's yeast; Antimicrobial activity

Novel biphenyl derivative as well as preparation method and medical application thereof

The invention relates to the field of medicinal chemistry, and discloses biphenyl derivatives with PD-1/PD-L1 inhibitory activity as well as a preparation method and application of the biphenyl derivatives. The invention further discloses a composition containing the biphenyl derivative with the PD-1/PD-L1 inhibitory activity or the pharmaceutically acceptable salt of the biphenyl derivative and a pharmaceutically acceptable carrier of the biphenyl derivative, and application of the biphenyl derivative in preparation of a PD-1/PD-L1 inhibitor. The compound can be used for treating tumors.

A predictive model for additions to: N -alkyl pyridiniums

Disclosed in this communication is a thorough study on the dearomative addition of organomagnesium nucleophiles to N-alkyl pyridinium electrophiles. The regiochemical outcomes have observable and predictable trends associated with the substituent patterns on the pyridinium electrophile. Often, the substituent effects can be either additive, giving high selectivities, or ablative, giving competing outcomes. Additionally, the nature of the organometallic nucleophilic component was also investigated for its role in the regioselective outcome. The effects of either reactive component are important to both the overall reactivity and site of nucleophilic addition. The utility of these observed trends is demonstrated in a concise, dearomative synthesis of a tricyclic compound shown to have insecticidal activity. This journal is

Nucleophile promoted gold redox catalysis with diazonium salts: C-Br, C-S and C-P bond formation through catalytic Sandmeyer coupling

Gold-catalyzed C-heteroatom (C-X) coupling reactions are evaluated without using sacrificial oxidants. Vital to the success of this methodology is the nucleophile-assisted activation of aryldiazonium salts, which could be an effective oxidant for converting Au(i) to Au(iii) even without the addition of an assisting ligand or photocatalyst. By accelerating the reaction kinetics to outcompete C-C homo-coupling or diazonium dediazoniation, gold-catalyzed Sandmeyer reactions were achieved with different nucleophiles, forming C-Br, C-S and C-P bonds in high yields and selectivities.

Design, Synthesis, and Evaluation of Novel Auxin Mimic Herbicides

Due to the key roles of auxins as master regulators of plant growth, there is considerable interest in the development of compounds with auxin-like properties for growth management and weed control applications. Herein, we describe the design and multiste

Pleuromutilin derivatives such, its pharmaceutical composition and synthetic method and use thereof

The present invention relates to a class of pleuromytilin compounds represented by the following general formula (I), pharmaceutically acceptable salts and preparation methods thereof, and compositions comprising the compound represented by the general fo

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF HEPATITIS C

Compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for i

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)